| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
Apelin receptor (APJ/APLNR); functions as a potent, high-affinity agonist with no binding to GPR15 or GPR25.
|
|---|---|
| ln Vitro |
ELA-32(human) TFA is a potent APJ agonist with high affinity: IC50=0.27 nM, Kd=0.51 nM. It activates the PI3K/AKT signaling pathway and promotes self-renewal of human embryonic stem cells (hESCs) via cell-cycle progression and protein translation. It also enhances the TGFbeta pathway, predisposing hESCs toward an endoderm lineage, and promotes angiogenesis in HUVEC cells.
|
| ln Vivo |
No detailed in vivo activity data are available for this specific TFA salt. The full-length ELA-32 peptide is expected to have similar in vivo effects as the active fragment Elabela(19-32), including vasodilation, reduced blood pressure, and positive inotropy.
|
| Enzyme Assay |
APJ receptor binding affinity (IC50=0.27 nM, Kd=0.51 nM) is assessed by competitive radioligand binding assays using [125I]-apelin-13 or [125I]-ELA-32 and membranes from HEK293 cells expressing human APJ; non-specific binding is determined with excess unlabeled ELA-32.
|
| Cell Assay |
Human embryonic stem cells (hESCs) are cultured in mTeSR1 medium containing ELA-32(human) TFA (100 nM) for 5-7 days; self-renewal is assessed by measuring pluripotency marker expression (OCT4, SOX2, NANOG) via qPCR and immunofluorescence; cell cycle progression is analyzed by flow cytometry.
|
| Animal Protocol |
Not available; standard in vivo protocol for APJ agonists in mice: intravenous administration at 0.1-10 nmol/kg; blood pressure measured via carotid artery catheter; cardiac function assessed by echocardiography. The TFA salt is formulated in saline for injection.
|
| ADME/Pharmacokinetics |
No dedicated PK data available for ELA-32(human) TFA. As a full-length 32-amino acid peptide, it is expected to have a very short plasma half-life (likely <5 minutes) due to rapid proteolytic degradation, similar to other small peptides.
|
| Toxicity/Toxicokinetics |
No toxicity data available; as a peptide, ELA-32(human) TFA is expected to have low toxicity at physiological concentrations. For research use only, not intended for human administration.
|
| Additional Infomation |
ELA-32(human) TFA is a research-grade peptide tool for studying APJ receptor biology, stem cell self-renewal, endoderm differentiation, and cardiovascular function. It has no clinical trial status or marketing approval as a therapeutic agent.
|
| Molecular Formula |
C172H290F3N63O41S4
|
|---|---|
| Molecular Weight |
4081.84
|
| Related CAS # |
ELA-32(human);1680205-79-1
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~100 mg/mL (~24.50 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (24.50 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.2450 mL | 1.2249 mL | 2.4499 mL | |
| 5 mM | 0.0490 mL | 0.2450 mL | 0.4900 mL | |
| 10 mM | 0.0245 mL | 0.1225 mL | 0.2450 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
